Special Issues

Special Issue Title: Breast Cancer

· Print Special Issue Flyer

· Deadline for manuscript submissions: 30 October 2021

Special Issue Editor

Guest Editor

Prof. Dr. Michael Friedrich

Department of Obstetrics and Gynecology, Helios Hospital Krefeld, Germany

Website | E-Mail

Interests: Gynecology; Obstetrics; Gynecological Oncology

Dr. Nicolò Bertozzi

U.O.C. of Hand Surgery and Reconstructive Microsurgery Unit, Santa Chiara Hospital, Pisa (PI), Italy

Website | E-Mail

Interests: Breast Cancer; Breast Reconstruction; Regenerative Medicin; Mesenchymal Stem Cells; Breast; Cosmetic Surgery; Breast Augmentation

Special Issue Information

Dear Colleagues,

Breast cancer is the most common cancer and the second cause of cancer deaths worldwide. Consequentely there is an urgent need to develop new therapeutic agents and treatment strategies that are effective against this cancer. Treatment options for patients suffering from breast cancerare classicicaly based on cytotoxic chemotherapy or antiestrogen treatment. New treatment startegies are directed towards newly identified targets. Thus breast cancer treatment is getting more and more tumor type specific resulting in an improved outcome combined with new side effects.

In this special issue the authors will present the most innovative treatment strategies for breast cancer based on the molecular patholological character of the tumor like luminal A/B, triple negative and Her2 overexpressing breast cancer. Thus, innovative endocrine treatment options for example CDK 4/6 inhibitors and PI3K-inhibitors will be discussed for endocrine responsibel berast cancer. In triple negative breast cancer the importance of neoadjuvant treatment is presented combined with the newly accepted inhibition of the PDL1 pathway. In addition the meaningful results of PARP inhibition in BRCA mutated breast cancer are analyzed. For Her2 overexpressing breast cancer all treatment options of inhibiting this pathway with regard to the actual studies are presented for the neoadjuvant, adjuvant, post neoadjuvant and metastatic setting are presented. Last but not least the actual recommendations for oncologic and oncoplastic surgery including sentinel lymph node resection are discussed.

This issue should give a summary of the modern treatment strategies in breast cancer with a special aspect on the actual guidelines and recommendation of the new systemic treatment options.

Prof. Dr. Michael Friedrich and Dr. Nicolò Bertozzi

Guest Editors


Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. Submitted papers should be well formatted and use good English.

Breast Cancer; Systemic Treatment; Adjuvant Setting; Metastatic Setting; Genetic Councelling; Triple Negative Breast Cancer; Her2+ Breast Cancer; Endocrine Treatment

Share This Special Issue


Planned Papers

Type: Review

Title: Circulating Tumor Cells in Early Breast Cancer: Current Evidence and Perspectives
Author: Maggie Banys-Paluchowski

Type: Original Research

Title: Feasibility of a Reduced Rate of Frozen Section Examination for Sentinel Node Biopsy in Breast Carcinoma
Author: Tommaso Susini

Type: Review

Title: Clinical Advances in the Treatment of Hormone-receptor Positive Breast Cancer
Author: Stefan Krämer

Type: Review

Title: Treatment Progress in Triple Negative Breast Cancer
Author: D. Saylan

Type: Review

Title: Therapy Landscape in HER2-receptor Positive Breast Cancer
Author: Dr. Med. M. Sellinger

Type: Original Research

Title: Oncoplastic Surgery and Axillary Management in Primary Breast Cancer
Author: M. Friedrich

Type: Review

Title: Multigene Signatures in Early Hormone Receptor-Positive, HER2-Negative Breast Cancer
Authors: Marcus Schmidt, Katrin Almstedt

Please wait a minute...
For Selected: Toggle Thumbnails
Role of sentinel node biopsy in breast cancer: a review
Maria Jesús Pla Farnós, Maria Eulalia Fernández-Montolí, Rosalía Pascal Capdevila, Amparo García Tejedor, Míriam Campos Delgado, Maite Bajen Lázaro, Anna Petit Montserrat, Raul Ortega Martínez, Evelyn Martínez Pérez, Sonia Pernas Simón, Jordi Ponce Sebastià
European Journal of Gynaecological Oncology    2021, 42 (5): 982-995.   DOI: 10.31083/j.ejgo4205147
Abstract76)   HTML10)    PDF(pc) (190KB)(62)       Save

Axillary lymph node involvement is still an important predictor of recurrence and survival in breast cancer. Axillary staging was classically done by axillary lymph node dissection (ALND), but the introduction of sentinel lymph node biopsy (SLNB) has led to a progressive and continuing de-escalation in its use. Therefore, SLNB can now be considered the standard procedure for axillary staging in clinically N0 patients. Different studies have also begun to report that a positive sentinel node does not always require ALND, reducing the morbidity derived from this technique. Fears that this sentinel node approach might not be accurate for neoadjuvant chemotherapy have been allayed by several studies showing that post-neoadjuvant SLNB in clinical N0 patients reduces the rate of ALND. This approach benefits from axillary pathological complete response with an acceptable false-negative rate. By contrast, however, cN1 disease still requires that we optimise the technique to reduce the rate of false negatives. Currently, SLNB is the best method for axillary staging in breast cancer, allowing patients to be treated according to risk of recurrence, and with good evidence that morbidity is lower than with other more radical techniques.
Related Articles | Metrics

Current Issue

  • Volume 42, Issue 5